444 related articles for article (PubMed ID: 29547565)
1. The Role of Post-Translational Modifications on Prion-Like Aggregation and Liquid-Phase Separation of FUS.
Rhoads SN; Monahan ZT; Yee DS; Shewmaker FP
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29547565
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of the FUS low-complexity domain disrupts phase separation, aggregation, and toxicity.
Monahan Z; Ryan VH; Janke AM; Burke KA; Rhoads SN; Zerze GH; O'Meally R; Dignon GL; Conicella AE; Zheng W; Best RB; Cole RN; Mittal J; Shewmaker F; Fawzi NL
EMBO J; 2017 Oct; 36(20):2951-2967. PubMed ID: 28790177
[TBL] [Abstract][Full Text] [Related]
3. The prion-like domain of Fused in Sarcoma is phosphorylated by multiple kinases affecting liquid- and solid-phase transitions.
Owen I; Rhoads S; Yee D; Wyne H; Gery K; Hannula I; Sundrum M; Shewmaker F
Mol Biol Cell; 2020 Nov; 31(23):2522-2536. PubMed ID: 32877292
[TBL] [Abstract][Full Text] [Related]
4. Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS.
Vazquez-Sanchez S; Tilkin B; Gasset-Rosa F; Zhang S; Piol D; McAlonis-Downes M; Artates J; Govea-Perez N; Verresen Y; Guo L; Cleveland DW; Shorter J; Da Cruz S
Mol Neurodegener; 2024 Jun; 19(1):46. PubMed ID: 38862967
[TBL] [Abstract][Full Text] [Related]
5. RNA-binding proteins with prion-like domains in health and disease.
Harrison AF; Shorter J
Biochem J; 2017 Apr; 474(8):1417-1438. PubMed ID: 28389532
[TBL] [Abstract][Full Text] [Related]
6. FUS interacts with nuclear matrix-associated protein SAFB1 as well as Matrin3 to regulate splicing and ligand-mediated transcription.
Yamaguchi A; Takanashi K
Sci Rep; 2016 Oct; 6():35195. PubMed ID: 27731383
[TBL] [Abstract][Full Text] [Related]
7. ALS/FTLD-Linked Mutations in FUS Glycine Residues Cause Accelerated Gelation and Reduced Interactions with Wild-Type FUS.
Rhine K; Makurath MA; Liu J; Skanchy S; Lopez C; Catalan KF; Ma Y; Fare CM; Shorter J; Ha T; Chemla YR; Myong S
Mol Cell; 2020 Nov; 80(4):666-681.e8. PubMed ID: 33159856
[TBL] [Abstract][Full Text] [Related]
8. Fused in Sarcoma: Properties, Self-Assembly and Correlation with Neurodegenerative Diseases.
Chen C; Ding X; Akram N; Xue S; Luo SZ
Molecules; 2019 Apr; 24(8):. PubMed ID: 31022909
[TBL] [Abstract][Full Text] [Related]
9. From nucleation to widespread propagation: A prion-like concept for ALS.
Maniecka Z; Polymenidou M
Virus Res; 2015 Sep; 207():94-105. PubMed ID: 25656065
[TBL] [Abstract][Full Text] [Related]
10. ATP enhances at low concentrations but dissolves at high concentrations liquid-liquid phase separation (LLPS) of ALS/FTD-causing FUS.
Kang J; Lim L; Song J
Biochem Biophys Res Commun; 2018 Oct; 504(2):545-551. PubMed ID: 30205960
[TBL] [Abstract][Full Text] [Related]
11. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation.
Patel A; Lee HO; Jawerth L; Maharana S; Jahnel M; Hein MY; Stoynov S; Mahamid J; Saha S; Franzmann TM; Pozniakovski A; Poser I; Maghelli N; Royer LA; Weigert M; Myers EW; Grill S; Drechsel D; Hyman AA; Alberti S
Cell; 2015 Aug; 162(5):1066-77. PubMed ID: 26317470
[TBL] [Abstract][Full Text] [Related]
12. ALS-causing hPFN1 mutants differentially disrupt LLPS of FUS prion-like domain.
Kang J; Lim L; Song J
Biochem Biophys Res Commun; 2023 Jul; 664():35-42. PubMed ID: 37130459
[TBL] [Abstract][Full Text] [Related]
13. Aggregation of FET Proteins as a Pathological Change in Amyotrophic Lateral Sclerosis.
Furukawa Y; Tokuda E
Adv Exp Med Biol; 2017; 925():1-12. PubMed ID: 27311318
[TBL] [Abstract][Full Text] [Related]
14. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.
Daigle JG; Lanson NA; Smith RB; Casci I; Maltare A; Monaghan J; Nichols CD; Kryndushkin D; Shewmaker F; Pandey UB
Hum Mol Genet; 2013 Mar; 22(6):1193-205. PubMed ID: 23257289
[TBL] [Abstract][Full Text] [Related]
15. Aggregation of ALS-linked FUS mutant sequesters RNA binding proteins and impairs RNA granules formation.
Takanashi K; Yamaguchi A
Biochem Biophys Res Commun; 2014 Sep; 452(3):600-7. PubMed ID: 25173930
[TBL] [Abstract][Full Text] [Related]
16. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
[TBL] [Abstract][Full Text] [Related]
17. The prionlike domain of FUS is multiphosphorylated following DNA damage without altering nuclear localization.
Rhoads SN; Monahan ZT; Yee DS; Leung AY; Newcombe CG; O'Meally RN; Cole RN; Shewmaker FP
Mol Biol Cell; 2018 Aug; 29(15):1786-1797. PubMed ID: 29897835
[TBL] [Abstract][Full Text] [Related]
18. A dynamic regulatory switch for phase separation of FUS protein: Zinc ions and zinc finger domain.
Chen Y; Pei X; Chen L; Chen L
Biochem Biophys Res Commun; 2024 May; 710():149862. PubMed ID: 38593618
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
20. FUS and TDP-43 Phases in Health and Disease.
Portz B; Lee BL; Shorter J
Trends Biochem Sci; 2021 Jul; 46(7):550-563. PubMed ID: 33446423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
